The PS-Ambrisentan Risk Evaluation and Mitigation Strategy (REMS) Program
A Risk Evaluation and Mitigation Strategy is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.
The PS-Ambrisentan REMS is a safety program that manages the risk of serious birth defects when taking ambrisentan. The PS-Ambrisentan REMS is required by the Food and Drug Administration (FDA).
Additional information including a list of participating companies and products
Information, tools and materials for patients taking ambrisentan
Dispense Authorization, resources, forms, enrollment, and educational materials for pharmacies
Resources, forms, enrollment, and educational materials for ambrisentan prescribers